Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25 Mar 23, 2021
Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10 Mar 4, 2021
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Feb 19, 2021
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Feb 17, 2021
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 Feb 16, 2021
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4 Feb 2, 2021
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market Jan 27, 2021
Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January Jan 6, 2021
